APX 005M

Drug Profile

APX 005M

Alternative Names: APX 005; APX 005M; EPI-0050

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Epitomics
  • Developer Apexigen; Parker Institute for Cancer Immunotherapy; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD40 antigen stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer
  • Phase I/II Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I Brain cancer; Glioma; Solid tumours

Most Recent Events

  • 06 Mar 2018 Apexigen in collaboration with the Paediatric Brain Tumor Consortium plan a phase I trial for Brain cancer (In children, In adolescents, Recurrent, Refractory metastatic disease)
  • 07 Dec 2017 Phase-I clinical trials in Brain cancer (In children, In adolescents, Recurrent, Refractory metastatic disease) in USA (Parenteral) (NCT03389802)
  • 07 Dec 2017 Phase-I clinical trials in Glioma (Newly diagnosed, In children, In adolescents) in USA (Parenteral) (NCT03389802)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top